Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials

Written By Carla Aguilera

Wieczorek A., Manzitti C., Garaventa A., Gray J., Papadakis V., Valteau-Couanet D., Zachwieja K., Poetschger U., Pribill I., Fiedler S., Ladenstein R., Lode HN

Cancers (Basel) 2022, 14(8), 1919; https://doi.org/10.3390/cancers14081919, 2022 April 10 (link 2)

Carla Aguilera
Previous

Suprarenal Masses in Very Young Infants: Is It Safe to Watch and Wait? Report of a SIOPEN Observational Study Results.
Next

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children…